Structure via PubChem · Public domain (PubChem)
paliperidone
Sign in to saveAlso known as 9-hydroxyrisperidone, Invega®, Ro-76477, Ro-92670, Trevicta, 9-Hydroxyrisperidone
Paliperidone, sold under the brand name Invega among others, is an atypical antipsychotic. It is used for the treatment of schizophrenia and schizoaffective disorder. It is marketed by Janssen Pharmaceuticals.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 461753832
- Drug.image
- Paliperidone.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.tradename
- Invega, others
- Drug.MedlinePlus
- a607005
- Drug.DailyMedID
- Paliperidone
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth, intramuscular
- Drug.class
- Atypical antipsychotic
- Drug.ATC_prefix
- N05
- Drug.ATC_suffix
- AX13
- Drug.legal_AU
- S4
- Drug.legal_BR
- C1
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C23H27FN4O3
- Molecular weight
- 426.5 g/mol
- IUPAC name
- 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
- SMILES
- CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
- InChIKey
- PMXMIIMHBWHSKN-UHFFFAOYSA-N
- XLogP
- 2.2
- Polar surface area
- 82.2 Ų
- H-bond donors
- 1
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Wikidata facts
- Mass
- 426.206719
Show 4 more facts
- chemical formula
- C₂₃H₂₇FN₄O₃
- Commons category
- Paliperidone
- canonical SMILES
- CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
- defined daily dose
- 2.5
Sources (6)
via Wikidata · CC0
~7 min read
Article
11 sectionsContents
- Medical use
- Adverse effects
- Pharmacology
- History
- Society and culture
- Deaths
- Suicides
- Homicides
- Brand names
- References
- External links
Paliperidone, sold under the brand name Invega among others, is an atypical antipsychotic. It is used for the treatment of schizophrenia and schizoaffective disorder. It is marketed by Janssen Pharmaceuticals.
Paliperidone was approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia in December 2006, and in the European Union in June 2007. Paliperidone palmitate is a long-acting injectable formulation of paliperidone palmitoyl ester. It is on the World Health Organization's List of Essential Medicines. Paliperidone is available as a generic medication.